Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
- Lorenza Rimassa
- , Giovanni Abbadessa
- , Nicola Personeni
- , Camillo Porta
- , Ivan Borbath
- , Bruno Daniele
- , Stefania Salvagni
- , Jean-Luc Van Laethem
- , Hans Van Vlierberghe
- , Jörg Trojan
- , Enrico N. De Toni
- , Alan Weiss
- , Steven Miles
- , Antonio Gasbarrini
- , Monica Lencioni
- , Maria E. Lamar
- , Yunxia Wang
- , Dale Shuster
- , Brian E. Schwartz
- , Armando Santoro
- IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
- ArQule, Inc.
- IRCCS Fondazione Policlinico San Matteo - Pavia
- Université catholique de Louvain
- Azienda Ospedaliera G. Rummo
- Alma Mater Studiorum University of Bologna
- Université libre de Bruxelles
- Ghent University
- Goethe University Frankfurt
- Ludwig Maximilian University of Munich
- University of British Columbia
- Cedar Sinai Hospital
- University of Pisa
- Daiichi Sankyo
Research output: Contribution to journal › Article
41
Link opens in a new tab
Citations
(Scopus)